Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.